1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Diabetic Neuropathy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Oral 1.2.3 Subcutaneous 1.2.4 Intravenous 1.3 Market by Application 1.3.1 Global Diabetic Neuropathy Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Online Pharmacies 1.3.3 Hospital Pharmacies 1.3.4 Retail Pharmacies 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Diabetic Neuropathy Market Perspective (2018-2029) 2.2 Diabetic Neuropathy Growth Trends by Region 2.2.1 Global Diabetic Neuropathy Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Diabetic Neuropathy Historic Market Size by Region (2018-2023) 2.2.3 Diabetic Neuropathy Forecasted Market Size by Region (2024-2029) 2.3 Diabetic Neuropathy Market Dynamics 2.3.1 Diabetic Neuropathy Industry Trends 2.3.2 Diabetic Neuropathy Market Drivers 2.3.3 Diabetic Neuropathy Market Challenges 2.3.4 Diabetic Neuropathy Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Diabetic Neuropathy Players by Revenue 3.1.1 Global Top Diabetic Neuropathy Players by Revenue (2018-2023) 3.1.2 Global Diabetic Neuropathy Revenue Market Share by Players (2018-2023) 3.2 Global Diabetic Neuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Diabetic Neuropathy Revenue 3.4 Global Diabetic Neuropathy Market Concentration Ratio 3.4.1 Global Diabetic Neuropathy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Diabetic Neuropathy Revenue in 2022 3.5 Diabetic Neuropathy Key Players Head office and Area Served 3.6 Key Players Diabetic Neuropathy Product Solution and Service 3.7 Date of Enter into Diabetic Neuropathy Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Diabetic Neuropathy Breakdown Data by Type 4.1 Global Diabetic Neuropathy Historic Market Size by Type (2018-2023) 4.2 Global Diabetic Neuropathy Forecasted Market Size by Type (2024-2029) 5 Diabetic Neuropathy Breakdown Data by Application 5.1 Global Diabetic Neuropathy Historic Market Size by Application (2018-2023) 5.2 Global Diabetic Neuropathy Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Diabetic Neuropathy Market Size (2018-2029) 6.2 North America Diabetic Neuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Diabetic Neuropathy Market Size by Country (2018-2023) 6.4 North America Diabetic Neuropathy Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Diabetic Neuropathy Market Size (2018-2029) 7.2 Europe Diabetic Neuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Diabetic Neuropathy Market Size by Country (2018-2023) 7.4 Europe Diabetic Neuropathy Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Diabetic Neuropathy Market Size (2018-2029) 8.2 Asia-Pacific Diabetic Neuropathy Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Diabetic Neuropathy Market Size by Region (2018-2023) 8.4 Asia-Pacific Diabetic Neuropathy Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Diabetic Neuropathy Market Size (2018-2029) 9.2 Latin America Diabetic Neuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Diabetic Neuropathy Market Size by Country (2018-2023) 9.4 Latin America Diabetic Neuropathy Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Diabetic Neuropathy Market Size (2018-2029) 10.2 Middle East & Africa Diabetic Neuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Diabetic Neuropathy Market Size by Country (2018-2023) 10.4 Middle East & Africa Diabetic Neuropathy Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Pfizer 11.1.1 Pfizer Company Detail 11.1.2 Pfizer Business Overview 11.1.3 Pfizer Diabetic Neuropathy Introduction 11.1.4 Pfizer Revenue in Diabetic Neuropathy Business (2018-2023) 11.1.5 Pfizer Recent Development 11.2 Janssen Pharmaceuticals 11.2.1 Janssen Pharmaceuticals Company Detail 11.2.2 Janssen Pharmaceuticals Business Overview 11.2.3 Janssen Pharmaceuticals Diabetic Neuropathy Introduction 11.2.4 Janssen Pharmaceuticals Revenue in Diabetic Neuropathy Business (2018-2023) 11.2.5 Janssen Pharmaceuticals Recent Development 11.3 Eli Lilly and Company 11.3.1 Eli Lilly and Company Company Detail 11.3.2 Eli Lilly and Company Business Overview 11.3.3 Eli Lilly and Company Diabetic Neuropathy Introduction 11.3.4 Eli Lilly and Company Revenue in Diabetic Neuropathy Business (2018-2023) 11.3.5 Eli Lilly and Company Recent Development 11.4 ACTAVIS 11.4.1 ACTAVIS Company Detail 11.4.2 ACTAVIS Business Overview 11.4.3 ACTAVIS Diabetic Neuropathy Introduction 11.4.4 ACTAVIS Revenue in Diabetic Neuropathy Business (2018-2023) 11.4.5 ACTAVIS Recent Development 11.5 Cephalon 11.5.1 Cephalon Company Detail 11.5.2 Cephalon Business Overview 11.5.3 Cephalon Diabetic Neuropathy Introduction 11.5.4 Cephalon Revenue in Diabetic Neuropathy Business (2018-2023) 11.5.5 Cephalon Recent Development 11.6 MEDA Pharma & Co. KG 11.6.1 MEDA Pharma & Co. KG Company Detail 11.6.2 MEDA Pharma & Co. KG Business Overview 11.6.3 MEDA Pharma & Co. KG Diabetic Neuropathy Introduction 11.6.4 MEDA Pharma & Co. KG Revenue in Diabetic Neuropathy Business (2018-2023) 11.6.5 MEDA Pharma & Co. KG Recent Development 11.7 GlaxoSmithKline 11.7.1 GlaxoSmithKline Company Detail 11.7.2 GlaxoSmithKline Business Overview 11.7.3 GlaxoSmithKline Diabetic Neuropathy Introduction 11.7.4 GlaxoSmithKline Revenue in Diabetic Neuropathy Business (2018-2023) 11.7.5 GlaxoSmithKline Recent Development 11.8 NeuroMetrix 11.8.1 NeuroMetrix Company Detail 11.8.2 NeuroMetrix Business Overview 11.8.3 NeuroMetrix Diabetic Neuropathy Introduction 11.8.4 NeuroMetrix Revenue in Diabetic Neuropathy Business (2018-2023) 11.8.5 NeuroMetrix Recent Development 11.9 Johnson & Johnson Services, Inc. 11.9.1 Johnson & Johnson Services, Inc. Company Detail 11.9.2 Johnson & Johnson Services, Inc. Business Overview 11.9.3 Johnson & Johnson Services, Inc. Diabetic Neuropathy Introduction 11.9.4 Johnson & Johnson Services, Inc. Revenue in Diabetic Neuropathy Business (2018-2023) 11.9.5 Johnson & Johnson Services, Inc. Recent Development 11.10 Novartis AG 11.10.1 Novartis AG Company Detail 11.10.2 Novartis AG Business Overview 11.10.3 Novartis AG Diabetic Neuropathy Introduction 11.10.4 Novartis AG Revenue in Diabetic Neuropathy Business (2018-2023) 11.10.5 Novartis AG Recent Development 11.11 DAIICHI SANKYO 11.11.1 DAIICHI SANKYO Company Detail 11.11.2 DAIICHI SANKYO Business Overview 11.11.3 DAIICHI SANKYO Diabetic Neuropathy Introduction 11.11.4 DAIICHI SANKYO Revenue in Diabetic Neuropathy Business (2018-2023) 11.11.5 DAIICHI SANKYO Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Diabetic Neuropathy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of Oral Table 3. Key Players of Subcutaneous Table 4. Key Players of Intravenous Table 5. Global Diabetic Neuropathy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 6. Global Diabetic Neuropathy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Diabetic Neuropathy Market Size by Region (2018-2023) & (US$ Million) Table 8. Global Diabetic Neuropathy Market Share by Region (2018-2023) Table 9. Global Diabetic Neuropathy Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 10. Global Diabetic Neuropathy Market Share by Region (2024-2029) Table 11. Diabetic Neuropathy Market Trends Table 12. Diabetic Neuropathy Market Drivers Table 13. Diabetic Neuropathy Market Challenges Table 14. Diabetic Neuropathy Market Restraints Table 15. Global Diabetic Neuropathy Revenue by Players (2018-2023) & (US$ Million) Table 16. Global Diabetic Neuropathy Market Share by Players (2018-2023) Table 17. Global Top Diabetic Neuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathy as of 2022) Table 18. Ranking of Global Top Diabetic Neuropathy Companies by Revenue (US$ Million) in 2022 Table 19. Global 5 Largest Players Market Share by Diabetic Neuropathy Revenue (CR5 and HHI) & (2018-2023) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Diabetic Neuropathy Product Solution and Service Table 22. Date of Enter into Diabetic Neuropathy Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Diabetic Neuropathy Market Size by Type (2018-2023) & (US$ Million) Table 25. Global Diabetic Neuropathy Revenue Market Share by Type (2018-2023) Table 26. Global Diabetic Neuropathy Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 27. Global Diabetic Neuropathy Revenue Market Share by Type (2024-2029) Table 28. Global Diabetic Neuropathy Market Size by Application (2018-2023) & (US$ Million) Table 29. Global Diabetic Neuropathy Revenue Market Share by Application (2018-2023) Table 30. Global Diabetic Neuropathy Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 31. Global Diabetic Neuropathy Revenue Market Share by Application (2024-2029) Table 32. North America Diabetic Neuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 33. North America Diabetic Neuropathy Market Size by Country (2018-2023) & (US$ Million) Table 34. North America Diabetic Neuropathy Market Size by Country (2024-2029) & (US$ Million) Table 35. Europe Diabetic Neuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 36. Europe Diabetic Neuropathy Market Size by Country (2018-2023) & (US$ Million) Table 37. Europe Diabetic Neuropathy Market Size by Country (2024-2029) & (US$ Million) Table 38. Asia-Pacific Diabetic Neuropathy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 39. Asia-Pacific Diabetic Neuropathy Market Size by Region (2018-2023) & (US$ Million) Table 40. Asia-Pacific Diabetic Neuropathy Market Size by Region (2024-2029) & (US$ Million) Table 41. Latin America Diabetic Neuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 42. Latin America Diabetic Neuropathy Market Size by Country (2018-2023) & (US$ Million) Table 43. Latin America Diabetic Neuropathy Market Size by Country (2024-2029) & (US$ Million) Table 44. Middle East & Africa Diabetic Neuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 45. Middle East & Africa Diabetic Neuropathy Market Size by Country (2018-2023) & (US$ Million) Table 46. Middle East & Africa Diabetic Neuropathy Market Size by Country (2024-2029) & (US$ Million) Table 47. Pfizer Company Detail Table 48. Pfizer Business Overview Table 49. Pfizer Diabetic Neuropathy Product Table 50. Pfizer Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 51. Pfizer Recent Development Table 52. Janssen Pharmaceuticals Company Detail Table 53. Janssen Pharmaceuticals Business Overview Table 54. Janssen Pharmaceuticals Diabetic Neuropathy Product Table 55. Janssen Pharmaceuticals Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 56. Janssen Pharmaceuticals Recent Development Table 57. Eli Lilly and Company Company Detail Table 58. Eli Lilly and Company Business Overview Table 59. Eli Lilly and Company Diabetic Neuropathy Product Table 60. Eli Lilly and Company Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 61. Eli Lilly and Company Recent Development Table 62. ACTAVIS Company Detail Table 63. ACTAVIS Business Overview Table 64. ACTAVIS Diabetic Neuropathy Product Table 65. ACTAVIS Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 66. ACTAVIS Recent Development Table 67. Cephalon Company Detail Table 68. Cephalon Business Overview Table 69. Cephalon Diabetic Neuropathy Product Table 70. Cephalon Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 71. Cephalon Recent Development Table 72. MEDA Pharma & Co. KG Company Detail Table 73. MEDA Pharma & Co. KG Business Overview Table 74. MEDA Pharma & Co. KG Diabetic Neuropathy Product Table 75. MEDA Pharma & Co. KG Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 76. MEDA Pharma & Co. KG Recent Development Table 77. GlaxoSmithKline Company Detail Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline Diabetic Neuropathy Product Table 80. GlaxoSmithKline Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 81. GlaxoSmithKline Recent Development Table 82. NeuroMetrix Company Detail Table 83. NeuroMetrix Business Overview Table 84. NeuroMetrix Diabetic Neuropathy Product Table 85. NeuroMetrix Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 86. NeuroMetrix Recent Development Table 87. Johnson & Johnson Services, Inc. Company Detail Table 88. Johnson & Johnson Services, Inc. Business Overview Table 89. Johnson & Johnson Services, Inc. Diabetic Neuropathy Product Table 90. Johnson & Johnson Services, Inc. Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 91. Johnson & Johnson Services, Inc. Recent Development Table 92. Novartis AG Company Detail Table 93. Novartis AG Business Overview Table 94. Novartis AG Diabetic Neuropathy Product Table 95. Novartis AG Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 96. Novartis AG Recent Development Table 97. DAIICHI SANKYO Company Detail Table 98. DAIICHI SANKYO Business Overview Table 99. DAIICHI SANKYO Diabetic Neuropathy Product Table 100. DAIICHI SANKYO Revenue in Diabetic Neuropathy Business (2018-2023) & (US$ Million) Table 101. DAIICHI SANKYO Recent Development Table 102. Research Programs/Design for This Report Table 103. Key Data Information from Secondary Sources Table 104. Key Data Information from Primary Sources List of Figures Figure 1. Global Diabetic Neuropathy Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Diabetic Neuropathy Market Share by Type: 2022 VS 2029 Figure 3. Oral Features Figure 4. Subcutaneous Features Figure 5. Intravenous Features Figure 6. Global Diabetic Neuropathy Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 7. Global Diabetic Neuropathy Market Share by Application: 2022 VS 2029 Figure 8. Online Pharmacies Case Studies Figure 9. Hospital Pharmacies Case Studies Figure 10. Retail Pharmacies Case Studies Figure 11. Diabetic Neuropathy Report Years Considered Figure 12. Global Diabetic Neuropathy Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 13. Global Diabetic Neuropathy Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 14. Global Diabetic Neuropathy Market Share by Region: 2022 VS 2029 Figure 15. Global Diabetic Neuropathy Market Share by Players in 2022 Figure 16. Global Top Diabetic Neuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathy as of 2022) Figure 17. The Top 10 and 5 Players Market Share by Diabetic Neuropathy Revenue in 2022 Figure 18. North America Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 19. North America Diabetic Neuropathy Market Share by Country (2018-2029) Figure 20. United States Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 21. Canada Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Europe Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Diabetic Neuropathy Market Share by Country (2018-2029) Figure 24. Germany Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 25. France Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. U.K. Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. Italy Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Russia Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Nordic Countries Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Asia-Pacific Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Asia-Pacific Diabetic Neuropathy Market Share by Region (2018-2029) Figure 32. China Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. Japan Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. South Korea Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. Southeast Asia Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. India Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. Australia Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Latin America Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Latin America Diabetic Neuropathy Market Share by Country (2018-2029) Figure 40. Mexico Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. Brazil Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Middle East & Africa Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Middle East & Africa Diabetic Neuropathy Market Share by Country (2018-2029) Figure 44. Turkey Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 45. Saudi Arabia Diabetic Neuropathy Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Pfizer Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 47. Janssen Pharmaceuticals Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 48. Eli Lilly and Company Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 49. ACTAVIS Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 50. Cephalon Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 51. MEDA Pharma & Co. KG Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 52. GlaxoSmithKline Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 53. NeuroMetrix Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 54. Johnson & Johnson Services, Inc. Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 55. Novartis AG Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 56. DAIICHI SANKYO Revenue Growth Rate in Diabetic Neuropathy Business (2018-2023) Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

Pfizer Janssen Pharmaceuticals Eli Lilly and Company ACTAVIS Cephalon MEDA Pharma & Co. KG GlaxoSmithKline NeuroMetrix Johnson & Johnson Services, Inc. Novartis AG DAIICHI SANKYO